Type of Cancer
Gynecologic
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.